WBB Securities initiated coverage of enGene (ENGN) with a Buy rating and $21.50 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene Therapeutics Rebrands as Company Nears Commercialization
- enGene Rebrands as enGene Therapeutics Ahead of Planned Bladder Cancer Gene Therapy Filing
- enGene Rebrands as enGene Therapeutics Ahead of Potential 2027 Commercial Launch
- enGene announces name change to enGene Therapeutics
- Three new option listings and three option delistings on April 6th